BlackRock
RANI icon

BlackRock’s Rani Therapeutics RANI Stock Holding History

BlackRock’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$409K Buy
556,889
+29,177
+6% +$37.3K ﹤0.01% 4583
2025
Q4 		$712K Buy
527,712
+407,480
+339% +$615K ﹤0.01% 4397
2025
Q3 		$60.1K Buy
120,232
+1,580
+1% +$823 ﹤0.01% 4949
2025
Q2 		$61K Buy
118,652
+55,069
+87% +$44.9K ﹤0.01% 4953
2025
Q1 		$80.1K Hold
63,583
– – ﹤0.01% 4821
2024
Q4 		$87.1K Hold
63,583
– – ﹤0.01% 4816
2024
Q3 		$137K Hold
63,583
– – ﹤0.01% 4610
2024
Q2 		$242K Hold
63,583
– – ﹤0.01% 4511
2024
Q1 		$198K Hold
63,583
– – ﹤0.01% 4582
2023
Q4 		$211K Hold
63,583
– – ﹤0.01% 4625
2023
Q3 		$138K Hold
63,583
– – ﹤0.01% 4771
2023
Q2 		$262K Hold
63,583
– – ﹤0.01% 4666
2023
Q1 		$328K Hold
63,583
– – ﹤0.01% 4648
2022
Q4 		$375K Sell
63,583
-139,324
-69% -$1.02M ﹤0.01% 4685
2022
Q3 		$1.94M Sell
202,907
-3,925
-2% -$41.6K ﹤0.01% 4213
2022
Q2 		$2.14M Buy
206,832
+49,458
+31% +$568K ﹤0.01% 4230
2022
Q1 		$2.13M Buy
157,374
+43,076
+38% +$715K ﹤0.01% 4363
2021
Q4 		$1.87M Buy
+114,298
New +$2.6M ﹤0.01% 4428

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock's RANI Position: Q1 2026 in Review

BlackRock increased its Rani Therapeutics (RANI) stake by 5.5% in Q1 2026, buying an estimated $37.3K and bringing the position to 556,889 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #4583.

BlackRock first reported a position in RANI in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.14M in Q2 2022. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • BlackRock held 556,889 shares of Rani Therapeutics worth $409K as of Q1 2026.
  • BlackRock bought 29,177 Rani Therapeutics shares in Q1 2026, an estimated $37.3K.
  • Rani Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4583 holding.
  • BlackRock first reported a position in Rani Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • BlackRock's Rani Therapeutics position peaked at $2.14M in Q2 2022.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.